Feature|Articles|September 11, 2023
- Pharmaceutical Executive: September 2023
- Volume 43
- Issue 9
Ahead of the Curve: Pharm Exec Profiles Five Recent Drug Launches
Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.
Advertisement
Follow the links below to read about each product:
Selections were made by Pharmaceutical Executive's editorial staff, with close input from Editorial Advisory Board members.
Articles in this issue
almost 3 years ago
Pharmaceutical Executive, September 2023 Issue (PDF)almost 3 years ago
A New Era of Ethical Leadershipalmost 3 years ago
Survival Story: Enhertualmost 3 years ago
Gut Instinct: Rebyotaalmost 3 years ago
Delaying Disease Onset: Tzieldalmost 3 years ago
New Beginnings: Sunlencaalmost 3 years ago
A Heartfelt Solution: Camzyosalmost 3 years ago
Fortifying Defenses Pre-Patent Cliffalmost 3 years ago
New Product Planning: The Function's Evolution in Pharmaalmost 3 years ago
No Rate Relief in Sight for BiotechAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Reading Between the Lines: Closing the T1D Misdiagnosis Gap
2
EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
3
The New Healthy Aging Imperative and What It Means for Pharma
4
Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics
5